Skip to main content

Table 3 Laboratory abnormalities of the two groups

From: Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma

  

Dose-reduced group (n = 57)

Dose-maintained group (n = 22)

 
  

All Grades n (%)

Grade 1/2 n (%)

Grade 3/4 n (%)

All Grades n (%)

Grade 1/2 n (%)

Grade 3/4 n (%)

p value

White blood cell count decreased

pretreatment

2 (3)

2 (3)

0 (0)

0 (0)

0 (0)

0 (0)

1.00

First 2 weeks

10 (18)

10 (18)

0 (0)

0 (0)

0 (0)

0 (0)

0.05

First cycle

33 (58)

29 (51)

4 (7)

11 (50)

10 (46)

1 (5)

0.61

Neutrophil count decreased

Pretreatment

1 (2)

1 (2)

0 (0)

0 (0)

0 (0)

0 (0)

1.00

First 2 weeks

3 (5)

3 (5)

0 (0)

1 (5)

1 (5)

0 (0)

1.00

First cycle

26 (46)

24 (42)

2 (3)

7 (32)

6 (27)

1 (5)

0.58

Lymphocyte count decreased

pretreatment

17 (30)

15 (27)

2 (3)

5 (23)

5 (23)

0 (0)

0.58

First 2 weeks

28 (49)

17 (30)

11 (19)

2 (9)

2 (9)

0 (0)

<0.01

First cycle

37 (65)

21 (37)

16 (28)

9 (41)

9 (41)

0 (0)

0.13

Hemoglobin decreased

pretreatment

43 (75)

38 (67)

5 (9)

14 (65)

11 (50)

3 (14)

0.40

First 2 weeks

38 (67)

35 (61)

3 (5)

14 (65)

14 (65)

0 (0)

0.80

First cycle

48 (84)

36 (63)

12 (21)

2 (9)

2 (9)

0 (0)

1.00

Platelet count decreased

pretreatment

7 (12)

7 (12)

0 (0)

9 (41)

9 (41)

0 (0)

1.00

First 2 weeks

37 (65)

34 (60)

3 (5)

8 (37)

7 (32)

1 (5)

0.03

First cycle

50 (89)

36 (64)

14 (25)

19 (86)

17 (77)

2 (9)

1.00

Creatinine increased

pretreatment

21 (37)

20 (36)

1 (2)

8 (36)

8 (36)

0 (0)

1.00

First 2 weeks

33 (58)

33 (58)

0 (0)

13 (59)

13 (59)

0 (0)

1.00

First cycle

33 (58)

32 (56)

1 (2)

13 (59)

13 (59)

0 (0)

1.00

Aspartate aminotransferase increased

pretreatment

10 (18)

10 (18)

0 (0)

2 (9)

2 (9)

0 (0)

0.49

First 2 weeks

34 (61)

32 (56)

2 (4)

8 (36)

8 (36)

0 (0)

0.08

First cycle

45 (79)

43 (76)

2 (4)

13 (59)

11 (50)

2 (9)

0.09

Alanine aminotransferase increased

pretreatment

13 (23)

13 (23)

0 (0)

3 (14)

3 (14)

0 (0)

0.53

First 2 weeks

26 (46)

25 (44)

1 (2)

7 (32)

7 (32)

0 (0)

0.79

First cycle

39 (68)

36 (63)

3 (5)

16 (73)

14 (64)

2 (9)

0.89

Hypoalbuminemia

pretreatment

38 (67)

37 (65)

1 (2)

10 (45)

9 (41)

1 (5)

0.12

First 2 weeks

52 (92)

48 (84)

4 (7)

17 (77)

15 (68)

2 (9)

0.24

First cycle

54 (95)

46 (81)

8 (14)

21 (95)

19 (86)

2 (9)

1.00

Blood bilirubin increased

pretreatment

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

N.D.

First 2 weeks

2 (4)

2 (4)

0 (0)

1 (5)

1 (5)

0 (0)

1.00

First cycle

4 (7)

3 (5)

1 (2)

2 (9)

2 (9)

0 (0)

0.67

Amylase increased

pretreatment

15 (26)

15 (27)

0 (0)

4 (18)

4 (18)

0 (0)

0.57

First 2 weeks

23 (40)

21 (37)

2 (4)

6 (27)

6 (27)

0 (0)

0.42

First cycle

33 (58)

23 (41)

10 (18)

9 (41)

8 (36)

1 (5)

0.20

Hyperuricemia

pretreatment

10 (18)

10 (18)

0 (0)

6 (27)

6 (27)

0 (0)

0.54

First 2 weeks

14 (25)

14 (25)

0 (0)

5 (23)

5 (23)

0 (0)

1.00

First cycle

14 (25)

14 (25)

0 (0)

7 (32)

7 (32)

0 (0)

0.57

Hypophosphatemia

pretreatment

4 (7)

2 (4)

2 (4)

3 (14)

2 (9)

1 (5)

0.40

First 2 weeks

10 (18)

8 (15)

2 (4)

0 (0)

0 (0)

0 (0)

0.05

First cycle

26 (46)

21 (37)

5 (9)

8 (36)

7 (32)

1 (5)

0.60

  1. Data are expressed in number of cases, with percentage in parenthesis